Executive Summary Chiral switching built billion-dollar franchises in the 1990s and early 2000s. The model was straightforward: isolate the active […]
Chiral Switching Is Dead as a Patent Play. Here’s Where It Still Makes Money. Read Post »
I. Why Generic Drug Economics Punish Mediocrity The generic drug market runs on a brutal arithmetic. Generics account for 90%
KSM designation is not a paperwork exercise. It is one of the earliest and highest-leverage decisions in pharmaceutical development, with
How to Find Key Starting Materials (KSMs) for Pharmaceutical APIs Read Post »
1. The Economic Architecture of the Patent Bargain 1a. What the Patent System Actually Incentivizes The pharmaceutical patent system rests
A definitive reference covering stereochemical science, the 1992 FDA policy and its commercial aftershocks, chiral separation technology roadmaps, Forest Labs
How to read the FDA’s most underused signal, map the Hatch-Waxman timeline with precision, and turn patent intelligence into a
FDA Tentative Approvals: The Definitive Guide to Forecasting Generic Drug Entry Read Post »
1. Why the PTAB Is the Single Most Important Variable in Pharmaceutical Patent Valuation Analysts who model pharmaceutical patent portfolios
The revenue locked inside a single patent grant can exceed the GDP of a small country. AbbVie’s Humira franchise generated
1. What Patent Opposition Actually Is, and What It Costs A patent opposition is a formal administrative procedure at a
Sign in or create a free account to read this DrugPatentWatch article
